Halozyme's 2026 Guide Jumped 31%-37%-Is the Stock Now Fairly Valued?

Halozyme's valuation now hinges on durability, not just a strong quarter

HALO can look expensive if you focus only on the headline multiple. After management raised 2026 guidance to $1.835 billion to $1.910 billion in revenue, $1.220 billion to $1.245 billion in royalty revenue, $1.225 billion to $1.280 billion in adjusted EBITDA, and $8.65 to $9.00 in non-GAAP EPS, the stock trades around a $11.70 billion market cap. That implies about 30.49x trailing P/E, 10.59x forward P/E, and 19.17x EV/EBITDA.

The real question is whether investors are paying for durable platform optionality or simply anchoring to one strong year. Against the prior quarter, when 2026 guidance was $1.710 billion to $1.810 billion and $7.75 to $8.25 in EPS, the reset was meaningful. HALO also reported five new ENHANZE and Hypercon collaborations year to date and $332.8 million in share repurchases in the second quarter. That supports the case that the business is still gaining external validation and generating strong cash flow.

If royalty growth and new partnerships keep building on each other, today's multiple may look more like a starting point than a peak. If that momentum cools, however, the stock could struggle because expectations have moved higher alongside the guidance.

Royalty breadth and platform deals are the core support for the multiple

The bullish case is not just about one good quarter. It is about a business model that can compound: commercial traction supports royalty revenue, and royalty revenue strengthens the company's ability to fund and attract more platform deals.

Royalty revenue is broadening

The latest quarter showed real breadth in the royalty engine. DARZALEX royalty revenue increased 27% to $152.2 million, Vyvgart Hytrulo royalties rose 143% to $72.6 million, and other royalty revenue grew 85% to $54.4 million. That mix lowers the risk that HALO is still dependent on a single hero asset. Older products are still contributing while newer launches begin to add to the base.

That growth is also coming through at high profitability. Management reported adjusted EBITDA margin above 65%, reinforcing that this is an established monetization engine rather than an experimental biotech asking the market for faith.

New collaboration agreements add optionality

The second part of the case is that commercial proof is helping attract partners. HALO has signed five new ENHANZE and Hypercon collaborations through July, ahead of its full-year goal of three. Each agreement is another data point that the platform can attach to additional molecules, partners, and potential royalty streams.

If that deal pace continues, investors may have a stronger case for paying for a repeatable royalty network rather than just one strong year. The main risk to that thesis is straightforward: if new licenses slow or newer products stop deepening the royalty mix, the rerating story loses force.

The guide raise widened the gap between execution and expectations

After a guidance increase of this magnitude, the setup becomes less about whether the company can execute and more about how much belief the market is already embedding in the stock.

From reaffirmation to raise

The shift from Q1 to Q2 captures that change. In May, HALO beat Q1 non-GAAP EPS, revenue rose 42.2%, but management only reaffirmed its full-year 2026 guidance. By August, the company had raised 2026 revenue guidance to $1.835 billion to $1.910 billion and lifted non-GAAP EPS guidance to $8.65 to $9.00.

Bulls will say the second quarter justified the reset. Bears will say the stock now has less room for a merely solid quarter. Once guidance moves from reaffirmation to a 31%-37% revenue growth range, investors tend to demand more than steady execution.

Profitability is strong, but the market still wants discipline

There are still reasons the model looks healthy. In Q1, operating margin was 49%, down from 53.4% a year earlier, a reminder that growth is still being paired with more investment. In Q2, R&D expenses rose to $27.7 million and SG&A increased to $57 million, while adjusted EBITDA margin remained above 65%. That is a sign of control, but it also shows how much weight the profitability case still carries.

If execution slips or the new guidance range proves too aggressive, the stock may be vulnerable to a multiple reset before the underlying business weakens.

Is HALO fairly valued after the reset?

HALO looks fairly valued to slightly undervalued if the next few quarters keep converting platform momentum into repeatable royalty evidence. A enterprise value of $13.65 billion and EV/EBITDA around 19.17 are not distressed levels. They suggest the market is already paying for durability, breadth, and future deal flow rather than just one strong year.

That valuation can still be justified. Recent results show five new ENHANZE and Hypercon collaborations through July, while royalty growth remains broad-based, including DARZALEX royalty revenue increased 27%, Vyvgart Hytrulo royalties rose 143%, and other royalty revenue grew 85%.

What the next earnings report needs to show

The next clean test is the November 9, 2026 earnings date. By then, the question is less whether HALO can have a good quarter and more whether the business is still adding evidence in the areas that matter most for valuation:

• royalty revenue keeps growing broadly, not from one isolated product
• new collaboration agreements continue to deepen the platform story
• profitability remains strong enough to support the market's durability assumption
• guidance stays inside or above the newly raised ranges
• management still shows a clear link between commercial traction and cash return

If those signals keep stacking up, the stock can still make the case that it is reasonably priced rather than fully priced. If they fade, HALO may still be a good business that simply no longer offers much room for rerating.